Magle Chemoswed Holding Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Magle Chemoswed Holding ha un patrimonio netto totale di SEK487.2M e un debito totale di SEK123.6M, che porta il suo rapporto debito/patrimonio netto a 25.4%. Le sue attività totali e le sue passività totali sono rispettivamente SEK857.2M e SEK370.0M. L'EBIT di Magle Chemoswed Holding è SEK25.5M rendendo il suo rapporto di copertura degli interessi 4.3. Ha liquidità e investimenti a breve termine pari a SEK7.3M.

Informazioni chiave

25.4%

Rapporto debito/patrimonio netto

SEK 123.59m

Debito

Indice di copertura degli interessi	4.3x
Contanti	SEK 7.26m
Patrimonio netto	SEK 487.19m
Totale passività	SEK 370.02m
Totale attività	SEK 857.20m

Aggiornamenti recenti sulla salute finanziaria

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Jun 19

Recent updates

Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher

Jun 26

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Jun 19

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality

Apr 26

Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%

Mar 29

Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings

Oct 05

Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?

Jan 22

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( { MAGLE di SEK206.2M ) non coprono le sue passività a breve termine ( SEK213.4M ).

Passività a lungo termine: Le attività a breve termine di MAGLE ( SEK206.2M ) superano le sue passività a lungo termine ( SEK156.6M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 23.9% ) di MAGLE è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di MAGLE è aumentato da 15% a 25.4% negli ultimi 5 anni.

Copertura del debito: Il debito di MAGLE non è ben coperto dal flusso di cassa operativo ( 10.6% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di MAGLE sono ben coperti dall'EBIT ( 4.3 x copertura).

Magle Chemoswed Holding Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) completed the acquisition of Amniotics AB (publ) (OM:AMNI).

New minor risk - Share price stability

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 16%

Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.27 in 1Q 2023)

Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial data availability

Magle Chemoswed Holding AB (publ) to Report Q4, 2024 Results on Feb 26, 2025

No independent directors

New minor risk - Share price stability

Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr0.87 (vs kr0.39 in FY 2021)

Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait

Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina

No independent directors

Magle Group Appoints New Chief Marketing and Innovation Officer

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding

Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®

Magle Chemoswed Holding AB (publ) Announces Post Market Clinical Study for SmartPAN®

Magle Chemoswed Holding AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Investor sentiment deteriorated over the past week

No independent directors

Full year 2021 earnings released: EPS: kr0.39 (vs kr0.24 in FY 2020)

Magle Chemoswed Holding AB (publ), Annual General Meeting, May 17, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Full year 2020 earnings released: EPS kr0.24

Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: kr44.60

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20 million.

New 90-day high: kr35.00

New 90-day high: kr34.60

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: kr33.50

New 90-day high: kr30.90

Magle Chemoswed Holding AB (Publ) Announces the Appointment of Joel Eklund as New Member of the Board

Magle Chemoswed Holding AB (publ) has completed an IPO in the amount of SEK 50 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane